AARTIPHARM
Aartipharm
Live Price
₹675.65
-8.70-1.27%
Conviction Scorecard
AI Momentum
18%Technical Rating
48%Analyst Sentiment
85%Market News & Buzz
📰
Recent news and updates for AARTIPHARM will appear here soon.
Stockmo Analyst Rationale
AI Generated Insight
"Caution advised for AARTIPHARM investors. AI signals correlate with a sustained bearish trend. Technical indicators suggest further consolidation within the healthcare sector before a reliable long-term bottom is established."
Verified by Stockmo Intelligence Grid
Supporting Evidence
Citing cross-referenced internal documents and market technicals
About Aartipharm
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Frequently asked questions
As of the latest market session, Aartipharm (AARTIPHARM) is trading at ₹675.65, representing a move of -1.27% from the previous close.
Aartipharm is listed and traded under the ticker symbol AARTIPHARM on the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE).
Today, Aartipharm's stock price moved by -1.27%. Long-term growth trends depend on company financials, technical moving averages, and sector momentum in the Healthcare industry.
Our proprietary AI Momentum engine calculates a 18% bullish probability for AARTIPHARM stock over the next 3-5 days. View the live interactive chart on Stockmo to see dynamic technical forecasting.
Over the past 52 weeks, Aartipharm shares reached a high of ₹954 and hit a low of ₹585.
AARTIPHARM exhibits standard volatility for a Healthcare stock, with an average daily trading volume of 59,177 shares. Detailed technical beta indicators are available on the Stockmo charting engine.
Aartipharm has a market capitalization of ₹6126.78 Cr, designating its size class inside the Healthcare sector.
Aartipharm has a current dividend yield of 58.00%. Companies may adjust payout ratios depending on quarterly earnings growth and reinvestment opportunities.
Aartipharm's trailing Price-to-Earnings (P/E) ratio is 35.14. This indicates how much investors are willing to pay for every rupee of the company's annual net earnings.
You can purchase Aartipharm (AARTIPHARM) shares through any SEBI-registered stockbroker (such as Kite/Zerodha, Groww, or Angel One) by funding your trading account and executing a buy order on the NSE or BSE.
Aartipharm's financial health, solvency, growth, and quality metrics are tracked using our proprietary Multibagger V2 score. You can explore AARTIPHARM's detailed 5-tier financial scorecard and compare it with market competitors on the Stockmo Multibagger Screener page.
Institutional order blocks and pristine support/resistance triggers for AARTIPHARM are monitored in real-time. View live technical entry levels, stop loss bounds, and target prices on our interactive Supply & Demand Trading Engine or scan entire market segments using the Basket Scanner.
Aartipharm operates inside the Healthcare sector. You can analyze sector-wide trends, relative strengths, and locate top emerging leaders in this space using our Sector Analysis Hub.